Device Trial Radar · NCT03734679
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (AVess FIH)
Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Dec 5, 2018
Primary completion
Feb 19, 2020
Study completion Jul 24, 2024
Sponsor
- Lead sponsor
- SurModics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 8, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and performance of the SurVeil DCB in subjects with obstructive lesions of arteriovenous fistulae for hemodialysis.
Conditions
- Hemodialysis Access Failure
Interventions
SurVeil Drug Coated BalloonDevice
Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Target Lesion Primary Patency at 6 Months Post ProcedureTime frame: 6 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Prince of Wales Private Hospital
Randwick, New South Wales, Australia
Auckland City Hospital
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.